{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"The anticipated/projected IHC-associated toxicities of greatest concern include: short-term toxicities- constitutional/systemic adverse events including fevers, hypotension, pulmonary infiltrates; long-term toxicities: autoimmune effects, graft-versus-host disease (GVHD), graft rejection. Toxicity will be measured by occurrence of any experimental treatment-related adverse events (AE) up to 12 weeks of completion of therapy. The CTCAE version 4.0 will be utilized for the description and grading of the AE. All symptoms, signs, or diseases assessed as experimental treatment-related will be captu","groups":[{"description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","id":"OG000","title":"Cohort I (Initial IHC Within 42 Days)"},{"description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","id":"OG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"no data was collected. Refers to the Cohort 1 Arm","reportingStatus":"POSTED","timeFrame":"Up to 12 weeks of completion of therapy","title":"the Number of Participants With Toxicities Associated With Administration of Irradiated Haploidentical Cells (IHC) Evaluated According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","type":"PRIMARY","unitOfMeasure":"Participants"}